Deutsche Bank AG Makes New Investment in United Therapeutics Corporation $UTHR

Posted by George Bondi on Aug 20th, 2026

Deutsche Bank AG purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 195,269 shares of the biotechnology company’s stock, valued at approximately $105,803,000.

Other hedge funds also recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP increased its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC raised its position in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC lifted its stake in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Norges Bank bought a new position in United Therapeutics during the fourth quarter worth about $293,418,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent research reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Read Our Latest Analysis on United Therapeutics

United Therapeutics Trading Up 2.1%

Shares of United Therapeutics stock opened at $529.14 on Thursday. The stock has a market capitalization of $22.69 billion, a price-to-earnings ratio of 18.93, a P/E/G ratio of 1.75 and a beta of 0.59. The firm’s 50-day moving average price is $534.23 and its two-hundred day moving average price is $537.17. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.41 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total value of $4,291,515.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $506.59, for a total value of $4,812,605.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $164,359,579.37. The trade was a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 434,275 shares of company stock valued at $235,371,678 over the last ninety days. Insiders own 8.60% of the company’s stock.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.